2,345,000 Shares in Immix Biopharma, Inc. $IMMX Bought by Opaleye Management Inc.

Opaleye Management Inc. purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,345,000 shares of the company’s stock, valued at approximately $24,177,000. Immix Biopharma makes up 2.2% of Opaleye Management Inc.’s holdings, making the stock its 11th largest holding. Opaleye Management Inc. owned 3.28% of Immix Biopharma as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Advisor Group LLC lifted its holdings in Immix Biopharma by 9.5% in the 1st quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock worth $316,000 after purchasing an additional 3,000 shares in the last quarter. Legal & General Group Plc purchased a new stake in Immix Biopharma during the 2nd quarter valued at approximately $41,000. Allworth Financial LP purchased a new stake in Immix Biopharma during the 4th quarter valued at approximately $30,000. California State Teachers Retirement System bought a new stake in shares of Immix Biopharma during the second quarter valued at approximately $566,000. Finally, Compass Financial Management LLC bought a new stake in shares of Immix Biopharma during the second quarter valued at approximately $56,000. 11.26% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IMMX shares. Citigroup reaffirmed a “market outperform” rating on shares of Immix Biopharma in a research note on Friday, August 14th. Morgan Stanley decreased their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Lifesci Capital started coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. HC Wainwright raised their price objective on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, Needham & Company LLC began coverage on Immix Biopharma in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $21.29.

Immix Biopharma Stock Up 3.2%

Immix Biopharma stock opened at $12.70 on Friday. The company has a market cap of $908.56 million, a price-to-earnings ratio of -14.43 and a beta of 0.20. The firm’s fifty day moving average is $11.25 and its 200 day moving average is $9.95. Immix Biopharma, Inc. has a 52-week low of $1.94 and a 52-week high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, equities research analysts anticipate that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.

Immix Biopharma Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.